vTv Therapeutics Inc. (VTVT) Form 8-K — May 13, 2026

$VTVTForm 8-KItems 2.02, 9.01Filed May 13, 2026, 4:18 PM ET0001641489-26-000019Original filing

vTv Therapeutics Inc. reported a net income of $24.1 million for the first quarter of 2026, a significant improvement from the net loss of $5.1 million in the same period last year. The company's revenue for the quarter was $36.8 million, driven by the $20.0 million upfront payment from an amendment to its license agreement with Newsoara Biopharma. The company's cash position increased to $98.1 million as of March 31, 2026, from $88.9 million as of December 31, 2025.

Key figures

Eps: 1.94
Revenue: 36839
Net Income: 24134
Total Debt: 8854
Cash Position: 98086

Price after filing

1 day: +21.4%7 days: +15.6%30 days: -0.2%

Close on the filing date to close N calendar days later (from $31.66). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.